• top_image

Supreme Court Strikes Down BRCA Gene Patents

June 13, 2013

The Supreme Court ruled unanimously on June 13 that private companies do not have the right to patent human genes, including those associated with an increased risk of ovarian and breast cancer - the BRCA1 and BRCA2 mutations. Many cancer advocates applauded the decision, in the hope it will allow for easier, less expensive access to genetic testing, and&amp;nbsp; more research to be done on these genes.Read the <link href="http://www.ovariancancer.org/2013/06/13/press-release-ovarian-cancer-advocates-praise-supreme-court-decision-on-gene-patents/">statement from the Alliance</link>.Read the <link href="http://www.nytimes.com/2013/06/14/us/supreme-court-rules-human-genes-may-not-be-patented.html?_r=0">New York Times story</link>.

The Supreme Court ruled unanimously on June 13 that private companies do not have the right to patent human genes, including those associated with an increased risk of ovarian and breast cancer - the BRCA1 and BRCA2 mutations. Many cancer advocates applauded the decision, in the hope it will allow for easier, less expensive access to genetic testing, and&amp;nbsp; more research to be done on these genes.
Read the <link href="http://www.ovariancancer.org/2013/06/13/press-release-ovarian-cancer-advocates-praise-supreme-court-decision-on-gene-patents/">statement from the Alliance</link>.
Read the <link href="http://www.nytimes.com/2013/06/14/us/supreme-court-rules-human-genes-may-not-be-patented.html?_r=0">New York Times story</link>.

Back